UNSPSC 51294905: Nuclotixene

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DTQ2MGV34. European Medicines Agency schedules Nuclotixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09389MIG. Nuclotixene generally arises in the molecular formula C21H20CLNS.

UNSPSC 51294905 Nuclotixene, a Commodity code, represents pharmaceutical products and drug-related systems that state and local governments procure for public health and community safety programs. Based on recent solicitations, the code encompasses naloxone (opioid reversal medication), safe drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment arrangements. State agencies dominate recent activity—the Texas Health and Human Services Commission, Minnesota Department of Administration, and county health departments such as Seminole County, Florida are the primary issuing bodies. The work ranges from straightforward product procurement through competitive bidding to complex cooperative purchasing agreements and exploratory vendor-capability assessments for state pharmacy benefit programs.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 (response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, with fixed-fee pricing and a two-year initial term plus one-year renewal option. The Minnesota Department of Administration, administering the Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026 (responses due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with pricing weighted at 75 percent and products required in the marketplace by May 15, 2026, effective July 1, 2026. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement activity around direct state-to-manufacturer pharmacy contracts.